2 recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 2 | Recruiting 2 |
Follow Dan Feng: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Dupilumab and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases Dupilumab, Toripalimab - Metastatic Colorectal Cancer, Liver Metastases | Phase 1 / Phase 2 | Recruiting | Dan Feng | 24 | 2026-09-01 | 2026-08-12 |
| Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC Nadunolimab, Toripalimab - Metastatic Microsatellite Stable Colorectal Carcinoma | Phase 1 / Phase 2 | Recruiting | Dan Feng | 24 | 2025-12-01 | 2026-02-19 |
toripalimab (2) · dupilumab (1)
United States (2)